ReviewCurrent cancer drug targets2016
Targeting Tumors with Small Molecule Peptides.
Review in Current cancer drug targets, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Ligand-modified liposomes as drug delivery systems for the active targeting of pancreatic cancer.International journal of pharmaceutics: X · 2026Review
- Elevating theranostics: The emergence and promise of radiopharmaceutical cell-targeting heterodimers in human cancers.iRadiology · 2024Article
- Peptide-Based Agents for Cancer Treatment: Current Applications and Future Directions.International journal of molecular sciences · 2023Review
- Peptide-based positron emission tomography probes: current strategies for synthesis and radiolabelling.RSC medicinal chemistry · 2023Review
- Computer-Assisted Design of Peptide-Based Radiotracers.International journal of molecular sciences · 2023Review
- Peptide Drug Conjugates and Their Role in Cancer Therapy.International journal of molecular sciences · 2023Review
- Engineering and Validation of a Peptide-Stabilized Poly(lactic-Bioconjugate chemistry · 2022Article
- Tripeptide-Stabilized Oil-in-Water Nanoemulsion of an Oleic Acids-Platinum(II) Conjugate as an Anticancer Nanomedicine.Bioconjugate chemistry · 2018Article
- Platinum (II) complex-nuclear localization sequence peptide hybrid for overcoming platinum resistance in cancer therapy.ACS biomaterials science & engineering · 2018Article
- Nanotherapeutic systems for local treatment of brain tumors.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2018Review
- Self-assembling prodrugs.Chemical Society reviews · 2017Review
- Anticancer effects of β-elemene with hyperthermia in lung cancer cells.Experimental and therapeutic medicine · 2017Article
- Molecular design and synthesis of self-assembling camptothecin drug amphiphiles.Acta pharmacologica Sinica · 2017Article
- Tumor-targeting peptides from combinatorial libraries.Advanced drug delivery reviews · 2017Review
- Regulating the Rate of Molecular Self-Assembly for Targeting Cancer Cells.Angewandte Chemie (International ed. in English) · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Chemotherapeutic treatment of cancers is a challenging endeavor, hindered by poor selectivity towards tumorous tissues over healthy ones. Preferentially delivering a given drug to tumor sites necessitates the use of targeting elements, of which there are a wide range in development. In this Review, we highlight recent examples of peptide-based targeting ligands that have been exploited to selectively deliver a chemotherapeutic payload to specific tumor-associated sites such as the vasculature, lymphatics, or cell surface. The advantages and limitations of such approaches will be discussed with a view to potential future development. Additionally, we will also examine how peptide-based ligands can be used diagnostically in the detection and characterization of cancers through their incorporation into imaging agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.